Patents by Inventor Nagarajan Muthukaman
Nagarajan Muthukaman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230286893Abstract: The present invention discloses a compound, Vanillylidenechloroacetone (VCA)—1-Chloro-4-(4?-hydroxy-3?-methoxy-phenyl)-but-3-en-2-one, and the process of preparing the same. The invention also discloses a process for synthesis of Calebin-A from Vanillylidenechloroacetone.Type: ApplicationFiled: March 3, 2023Publication date: September 14, 2023Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Nagarajan Muthukaman, Paradesi Naidu Pentakota
-
Publication number: 20220388939Abstract: The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.Type: ApplicationFiled: May 26, 2022Publication date: December 8, 2022Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Nagarajan Muthukaman, Pentakota Paradesi Naidu
-
Patent number: 10821100Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: May 28, 2019Date of Patent: November 3, 2020Assignee: Ichnos Sciences SAInventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Patent number: 10457649Abstract: The present application relates to solid state forms of a triazolone compound which exhibit mPGES-1 enzyme inhibition activity, specifically N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl)pivalamide (Compound of formula II), and process for preparation thereof.Type: GrantFiled: August 31, 2018Date of Patent: October 29, 2019Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Nagarajan Muthukaman, Laxmikant A. Gharat, Suresh M. Kadam, Sachin Gavhane, Sandeep B. Khandagale, Sunil P. Nirgude
-
Publication number: 20190282548Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: May 28, 2019Publication date: September 19, 2019Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Patent number: 10391083Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: March 13, 2018Date of Patent: August 27, 2019Assignee: GLENMARK PHARMACEUTICALS S.AInventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Publication number: 20180370923Abstract: The present application relates to solid state forms of a triazolone compound which exhibit mPGES-1 enzyme inhibition activity, specifically N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl) pivalamide (Compound of formula II), and process for preparation thereof.Type: ApplicationFiled: August 31, 2018Publication date: December 27, 2018Inventors: Nagarajan Muthukaman, Laxmikant A. Gharat, Suresh M. Kadam, Sachin Gavhane, Sandeep B. Khandagale, Sunil P. Nirgude
-
Patent number: 10112914Abstract: The present application relates to solid state forms of a triazolone compound which exhibit mPGES-1 enzyme inhibition activity, specifically N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl) pivalamide (Compound of formula II), and process for preparation thereof.Type: GrantFiled: June 13, 2016Date of Patent: October 30, 2018Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Nagarajan Muthukaman, Laxmikant A. Gharat, Suresh M. Kadam, Sachin Gavhane, Sandeep B. Khandagale, Sunil P. Nirgude
-
Publication number: 20180200229Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: March 13, 2018Publication date: July 19, 2018Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Publication number: 20180134671Abstract: The present application relates to solid state forms of a triazolone compound which exhibit mPGES-1 enzyme inhibition activity, specifically N-(4-chloro-3-(5-oxo-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)benzyl) pivalamide (Compound of formula II), and process for preparation thereof.Type: ApplicationFiled: June 13, 2016Publication date: May 17, 2018Inventors: Nagarajan Muthukaman, Laxmikant A. Gharat, Suresh M. Kadam, Sachin Gavhane, Sandeep B. Khandagale, Sunil P. Nirgude
-
Patent number: 9949955Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: August 4, 2016Date of Patent: April 24, 2018Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Publication number: 20160339000Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: August 4, 2016Publication date: November 24, 2016Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Patent number: 9439890Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: June 19, 2015Date of Patent: September 13, 2016Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Publication number: 20150283117Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as raPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: June 19, 2015Publication date: October 8, 2015Inventors: Laxmikant A. GHARAT, Nagarajan MUTHUKAMAN, Neelima KHAIRATKAR-JOSHI, Vidya G. KATTIGE
-
Patent number: 9096545Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: June 10, 2013Date of Patent: August 4, 2015Assignee: GLENMARK PHARMACEUTICALS S.A.Inventors: Laxmikant Atmaram Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Publication number: 20150087646Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: June 10, 2013Publication date: March 26, 2015Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Laxmikant Atmaram Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Patent number: 8519149Abstract: The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: October 28, 2011Date of Patent: August 27, 2013Assignee: Glenmark Pharmaceuticals S.A.Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Lakshminarayana Narayana, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Publication number: 20120108583Abstract: The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: ApplicationFiled: October 28, 2011Publication date: May 3, 2012Applicant: Glenmark Pharmaceuticals S.A.Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Lakshminarayana Narayana, Neelima Khairatkar-Joshi, Vidya G. Kattige
-
Publication number: 20080009535Abstract: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.Type: ApplicationFiled: March 27, 2006Publication date: January 10, 2008Inventors: Sarala Balachandran, Nidhi Gupta, Nagarajan Muthukaman, Vinayak Khairnar, Sarika Ramnani, Lalit Baregama, Saswati Chakladar, Mandadapu Raghu Ramaiah, Ritu Agarwal, Sunanda Dastidar, Abhijit Ray